T2 Biosystems (TTOO) Q2 2024 earnings summary

Executive summary

• Achieved record sepsis test revenue in Q2 2024, up 27% year-over-year, driven by T2Bacteria and T2Resistance panels, with total revenue flat at $2.0 million due to lower instrument sales.

• Expanded international presence with exclusive distribution agreements in Qatar, Hong Kong, Macao, Malaysia, and Indonesia, and executed contracts for 8 T2Dx instruments.

• Ongoing negotiations for a major U.S. commercial partnership to scale distribution.

• Product pipeline includes T2 Resistance Panel, T2Lyme Panel, and expanded T2 Candida Panel, all with FDA breakthrough device designation.

• Operational improvements include significant debt reduction, cost savings, and a 30% headcount reduction since early 2023.

Financial highlights

• Q2 2024 revenue was $2.0 million, all from sepsis product sales, flat year-over-year.

• Sepsis test panel sales up 27% year-over-year and 12% sequentially.

• Cost of product revenue decreased 45% year-over-year to $2.7 million, driven by manufacturing efficiencies and lower instrument sales.

• Net loss for Q2 2024 was $9.2 million ($0.66 per share), compared to $6.3 million ($7.84 per share) in Q2 2023; loss from operations improved 27% to $9.6 million.

• Cash and cash equivalents were $4.2 million as of June 30, 2024, with $7.3–$9.5 million raised via private placement and equity sales.

Outlook and guidance

• 2024 revenue guidance for sepsis and related products is $10–$11 million, representing 49%–64% growth over 2023.

• H2 2024 expected to account for 60% of annual revenue, with strong international instrument sales anticipated.

• Guidance excludes potential upside from T2 Biothreat and T2Lyme panels.

• U.S. T2 Resistance Panel 510(k) submission planned for Q4 2024; T2Lyme Panel launch as a lab-developed test expected in Q3 2024.

• Management is exploring strategic alternatives, including M&A or asset sales, due to insufficient cash to fund operations beyond mid-Q3 2024.